PharmAla reports a US$100 million ALA-002 licensing deal and New Zealand approval of MDMA-assisted PTSD therapy

PharmAla's first quarterly roundup highlights a US licensing agreement for ALA-002 with Jupiter Neurosciences, valued at up to US$100 million. PharmAla receives US$3.33 million upfront, may earn up to US$96.7 million in development and sales milestones, and will receive a 3% royalty on US net sales after those milestones, while retaining rights outside the United States. The company also reports a new US patent covering single-enantiomer MDMA and MBDB processes, continued full ownership of APA-01, and a new investment banking partnership. In regulatory news, New Zealand's Medsafe approved two psychiatrists to prescribe pharmaceutical-grade MDMA for treatment-resistant PTSD in supervised settings. The roundup also mentions a reportedly resubmitted FDA application for MDMA-assisted therapy, while noting PharmAla cannot confirm the filing's status.